Launch over-the-counter NARCAN Nasal Spray
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 9 May 2023
- Due
- 30 Sep 2023
- Delivered
- Q3 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“targeting late summer launch”
What we found
Evidence strength A What the grades mean
The company confirmed in its filings that it launched the over-the-counter NARCAN Nasal Spray beginning in the third quarter of 2023, which aligns with the late summer 2023 deadline.
-
A Emergent BioSolutions Inc. 10-Q filed 2023-12-11
“Beginning in the third quarter of 2023, the Company launched the over-the-counter NARCAN® (naloxone HCl) Nasal Spray, 4mg (“NARCAN® OTC”)” ✓ confirmed on the page
Market reaction: the shares moved -10.3% against the S&P 500 over the three sessions around the disclosure (8 Dec 2023 to 13 Dec 2023). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Commercial launch
- Indicative materiality
- Medium rules
- Action
- Launch
- Deliverable
- Over-the-counter NARCAN Nasal Spray
- Language
- Aspirational (“aims”, “intends”)
- In the company’s control
- High
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Emergent BioSolutions Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-EBS-002482 · Corrections policy